Comparison of Intraocular Pressure, Blood Pressure, Ocular Perfusion Pressure and Blood Flow Fluctuations During Dorzolamide Versus Timolol Add-On Therapy in Prostaglandin Analogue Treated Glaucoma Subjects
| Autor: | Alon Harris, Vaida Diliene, Daiva Paulaviciute-Baikstiene, Ingrida Januleviciene, Brent Siesky, Lina Siaudvytyte, Ruta Barsauskaite |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2012 |
| Předmět: |
medicine.medical_specialty
Intraocular pressure genetic structures medicine.drug_class Pharmaceutical Science Timolol open-angle glaucoma lcsh:Medicine lcsh:RS1-441 color dopler imaging Article lcsh:Pharmacy and materia medica chemistry.chemical_compound Dorzolamide Ophthalmology Drug Discovery medicine retrobulbar blood flow Latanoprost Morning business.industry lcsh:R ocular perfussion pressure eye diseases medicine.anatomical_structure Blood pressure chemistry Vascular resistance Molecular Medicine sense organs Prostaglandin analogue business medicine.drug intraocular pressure |
| Zdroj: | Pharmaceuticals, Vol 5, Iss 3, Pp 325-338 (2012) Pharmaceuticals Volume 5 Issue 3 Pages 325-338 |
| ISSN: | 1424-8247 |
| Popis: | Objective: To compare the effects of dorzolamide and timolol add-on therapy in open-angle glaucoma (OAG) patients previously treated with prostaglandin analogue (Pg), by evaluating fluctuations in the intraocular (IOP), blood (BP), ocular perfusion pressures (OPP) and retrobulbar blood flow (RBF) parameters. Methods: 35 OAG patients (35 eyes), 31 women (88.6%) age 63.3 (8.9) years were evaluated in a 3 month randomized, cross-over, single-masked study. During the experiments BP, heart rate, IOP and OPP were assessed 4 times per day (8–12–16–20 h). RBF was measured twice per day (8–20 h) using Color Doppler imaging in the ophthalmic (OA), central retinal (CRA), nasal (nSPCA) and temporal (tSPCA) posterior ciliary arteries. In each vessel, peak systolic velocity (PSV) and end-diastolic velocity (EDV) were assessed and vascular resistance (RI) calculated. Results: Both add-on therapies lowered IOP in a statistically significant manner from 15.7 ± 2.4 mmHg at latanoprost baseline to 14.9 ± 2.2 mmHg using dorzolamide (p p vs. 0.2 ± 2.1 mmHg), (p p = 0.01). With increased MAP in the morning or evening hours, we found increased evening OA RI in timolol add-on group (c = 0.400, p = 0.02 c = 0.513, p = 0.002 accordingly). Higher MAP fluctuations were related to impaired RBF parameters during evening hours-decreased CRA EDV (c = −0.408 p = 0.01), increased CRA RI (c = 0.576 p p = 0.04) in the dorzolamide group and increased nSPCA RI (c = 0.351 p = 0.04) in the timolol add-on group. OPP fluctuations correlated with increased nSPCA RI (c = 0.453 p = 0.006) in the timolol group. OPP fluctuations were not related to IOP fluctuations in both add-on therapies (p < 0.05). Conclusions: Both dorzolamide and timolol add-on therapies lowered IOP in a statistically significant fashion dorzolamide add-on therapy showed lower fluctuations in IOP, SPP and BP. Higher variability of daytime OPP led to impaired RBF parameters in the evening. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|